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Background: A pivotal, randomized, phase III trial demonstrated a statistically 
significant superiority of sunitinib over interferon-α in metastatic renal cell carcinoma 
(mRCC) patients.  
 Objective: To evaluate the effectiveness and safety of sunitinib in patients with 
advanced or mRCC in routine clinical practice. 
Methods: Retrospective pooled analysis of clinical data from three observational and 
prospective studies carried out between 2007 and 2011 in 33 Spanish hospitals. Tumor 
response, Progression-free survival (PFS) and overall survival (OS), and main sunitinib-
related toxicities were registered. 
Results. 224 patients were analyzed. Median PFS 10.6 months (95% CI: 9.02-12.25), 
median OS 21.9 months (95% CI: 17.2-26.6).  Objective response rate (ORR) 43.8% 
(95% CI: 36.8-50.7). Median time to PR was 3.8 months (95% CI: 3.86-5.99) and to CR 
8.2 months (95% CI: 4.75-9.77). The most common ≥ grade-3 AEs were 
asthenia/fatigue (18.7%), hand-foot syndrome (6.2%), hypertension (5.8%) and 
neutropenia (4.8%). Hand-foot syndrome, diarrhea and mucositis were confirmed as 
independent predictors for PFS and/or OS in a multivariate analysis (p<0.05)  
Conclusions. Outcomes with sunitinib in daily clinical practice resemble those obtained 
in clinical trials. Long-term benefit with sunitinib is possible in advanced RCC patients 
but the appropriate management of toxicities is mandatory to enable patients to remain 
on treatment.  






Article highlights  
• Observational studies in patients treated under common clinical conditions are 
needed in addition to clinical trials.  
• Outcomes with sunitinib in daily clinical practice resemble those obtained in 
clinical trials, however new schemes of administration (2 wks on/ 1 wks off9 




Renal cell carcinoma is the most common cancer of the kidney1. Approximately 
one  third of patients present at initial diagnosis with evidence of metastases 2, and  local 
recurrence or distant metastasis develops up to 40% of the patients treated for localized 
tumors 1.  
Targeted therapies have led to clinically meaningful advances in the treatment of 
patients with metastatic renal carcinoma (mRCC)3.  
Sunitinib malate (Sutent®, Pfizer), an oral multi-targeted receptor tyrosine kinase 
inhibitor (TKI), is a potent inhibitor of vascular endothelial growth factor receptor 
(VEGFR), platelet-derived growth factor receptor (PDGFR) and other tyrosine kinase 
receptors4, 5. Sunitinib is a standard of care for first-line treatment of mRCC6. Motzer et 
al  in a pivotal, randomized and phase III trial conducted in 750 treatment-naïve clear 
cell mRCC patients, demonstrated a statistically significant superiority of sunitinib over 
interferon-α in progression-free survival (PFS) (11 vs. 5 months; p>0.001) 7 and 
objective response rate (ORR) (47% vs. 12%; p<0.001)8. In addition, a greater overall 
survival (OS) trend (26.4 vs. 21.8 months; p=0.051)8 was also observed.  
Gore et al in an expanded access study with 4,543 locally advanced or 
mestastatic RCC patients on sunitinib treatment, including patients with ECOG ≥2 
(15%), brain metastases (7%), and non-clear-cell histology (12%), reported a median 
PFS of 9.4 months and a safety profile consistent with the initial phase III trial 
mentioned above 9. 
Observational studies in patients treated under common clinical conditions are 
needed in addition to clinical trials. Here, we carried out a pooled analysis of clinical 
data of patients from three observational and prospective studies aimed to identify 
biomarkers of response to sunitinb 10-13.  
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The objective of the present retrospective analysis was to assess whether 
sunitinib efficacy and safety outcomes reported in the pivotal trial and in the expanded 
access study were also reproduced in our Spanish population of patients.  
2.- Patients and Methods 
We here describe a retrospective pooled analysis of data from 224 evaluable 
patients out of the 233 enrolled in three observational and prospective studies SUT-IIG-
9 (N=49)10, SUTREN-07 (N=94) 11, 12 13 and MAR-SUT-2008-01 (N=81) aimed at 
evaluating the predictive value in terms of efficacy of different biomarkers. The reasons 
for exclusion of 9 (3.9%) patients included screening failure 7 (77.8%), patient’s death 1 
(11.1%) and no available data 1 (11.1%). These studies were carried out between 2007 
and 2011 in 33 Spanish hospitals. 
Common eligibility criteria for all patients in these studies included ≥ 18 years 
of age, histologically confirmed RCC, and locally advanced or metastatic disease. 
Patients received sunitinib as first-line systemic treatment in a daily clinical practice 
setting, initiating treatment in most cases at a standard dose and schedule (50mg/d, 4 
weeks on, 2 weeks off).  
Written informed consent was obtained from all patients. In accordance with the 
Spanish regulations, all studies were approved by the Ethics Committee of all 
participating institutions, and were conducted in compliance with the principles 
contained in the Declaration of Helsinki for studies in humans.  
Statistical analysis 
 
PFS was defined as the time between the first day of treatment with sunitinib 
and the date of radiological progressive disease (PD), clear clinical evidence of PD or 
death.  Patients who had not progressed at database closure were censored at final 
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follow-up. OS was defined as the time between the first day of sunitinib treatment and 
the date of death from any cause. Patients who had not died at database closure were 
censored at final follow-up. ORR was defined as the proportion of patients with either a 
complete response (CR) or a partial response (PR) and disease control rate was defined 
as the proportion of patients with an ORR or a stable disease (SD). Tumor assessments 
according to Response Evaluation Criteria in Solid Tumors (RECIST)14 were done in 
accordance with current local practice guidelines for patients with RCC. 
Main sunitinib-related toxicities (mucositis, asthenia/fatigue, diarrhea, 
neutropenia, hypertension, hand-foot syndrome and hypothyroidsm) were registered. 
Adverse events (AEs) were assessed according to the National Cancer Institute 
Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3.0 or 
version 4.0. Other toxicities were also recorded but severity was not graded. AEs 
leading to dose reductions and the date on which they occurred were registered. 
Sunitinib treatment schedule and dose, including median duration of therapy, and dose 
reductions were also recorded.  
Memorial Sloan-Kettering Cancer Center (MSKCC)15 criteria were used in this 
analysis considering the following variables as poor risk: Time from diagnosis to 
treatment less than 12 months, Karnofsky performance status (KPS) < 80% or Eastern 
Cooperative Oncology Group performance status (ECOG) ≥2, serum lactate 
dehydrogenase (LDH) more than 1.5-times the upper limit of normal (ULN), corrected 
serum calcium >10mg/dl and hemoglobin less than the lower limit of normal (LLN). 
Patients were grouped according to prognostic risk category on the basis of MSKCC15 
criteria: favorable (0 risk factors), intermediate (1 or 2 risk factors) and poor (≥ 3 risk 
factors).  
2.1 Statistical analyses 
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All data were presented using descriptive statistics. Quantitative and qualitative 
variables were analyzed using measurements of central tendency and dispersion (95% 
confidence interval [CI]). Qualitative variables were defined according to their absolute 
and relative frequencies. Quantitative variables were described with mean and standard 
deviation. Median PFS and OS were estimated using the Kaplan Meier method. Both 
univariate and multivariate Cox regression models were used to identify potential 
prognostic factors for PFS and OS. Each variable was investigated by univariate and 
thereafter, the variables with a significance of p<0.05 were used for multivariate 
analysis. Tests were two-tailed with a significance level of 5%. Data were analysed 
using SPSS statistical software v17.0. 
3.- Results 
Baseline demographic and clinical characteristics of the 224 patients analyzed 
are summarized in table 1. Patients from the three studies included in this analysis were 
predominantly men with a median age (range) at study inclusion of 64.1(32.5-87.3) 
years. Eighty one percent had a prior nephrectomy. The majority had clear cell 
histology (92.7%) or a clear cell component and presented favorable or intermediate 
prognostic risk according to MSKCC criteria (88.9%) when they started treatment. 
Ninety-three (42.3%) patients presented with metastatic disease at the time of diagnosis. 
Lung was the most common site of metastasis (70.3%) and 3.2% of the patients 
presented brain metastases (Table 1). The time interval from diagnosis to sunitinib was 
≤ 1 year in 129 patients (58.1%).  
3.1 Treatment administration 
Median duration of treatment was 7.7 months (Interquartile range (IQR) Q1-
Q3:3.7-13.0). Of the overall population, 89.3% started on a dose of 50 mg given once 
daily for 4 weeks, followed by 2 weeks without treatment (schedule 4/2), the standard 
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dose and schedule for local advanced or mRCC; 4.5% and 4.9% of patients initiated 
treatment with a daily continuous dose of 37.5 mg and of 25 mg, respectively. One 
hundred and twenty two (55%) patients had at least one dose reduction during sunitinib 
treatment. Of these, 55% reduced dose only once and the remaining 45% at least twice. 
Eight (6.6%) patients reduced dose during the first cycle of treatment, 38 (31.1%) 
during the second cycle, and 96 (79%) during the third cycle or beyond. Toxicity was 
the main reason for dose reduction in 73.8% of patients. 
One hundred and seventy-one (76%) patients had discontinued treatment at the 
time of the analysis; 116 (68%) due to progressive disease, 34 (20%) due to adverse 
events and 30 (18%) for other reasons There could be more than one reason for 
discontinuation for each patient.  
3.2 Efficacy 
Table 2 and Figure 1 show the median PFS and OS according to MSKCC 
criteria.  At a median follow-up of 13.1 months (IQR: Q1-Q3: 7.0-22.2) the median PFS 
for all patients was 10.6 months (95% CI: 9.02-12.25).  Patients with a favorable 
prognosis achieved the highest median PFS (18.0 months; p<0.001; Table 2 and 
Figure1).  
At the time of the analysis 102 (46%) patients had died. Median OS was 21.9 
(95% CI 17.2-26.6) months in the overall population. In patients with favorable-risk 
features the median OS had not been reached at the time of the analysis; median OS for 
intermediate and poor risk groups (MSKCC criteria) was 22.4 months (95% IC: 15.37-
29.43) and 7.7 (4.58-10.82) respectively (Table 2, Figure 2) 
Of the overall population, 208 (92.9%) patients were evaluable for tumor 
response; 5.3% had a CR and 38.5% a PR, yielding an ORR of 43.8% (95% CI: 36.8-
50.7; Table 3). Eighty (38.5%) patients exhibited stable disease (SD), 80% of them for 
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more than 6 months, resulting in a disease control rate (PR+CR+SD) of 82% (Table 3). 
Median time to PR was 3.8 months (95% CI: 3.86-5.99) and to CR 8.2 months (95% CI: 
4.75-9.77). Median (Q1-Q3) duration of response (PR or CR) was 7.4 (4.1-16.2) 
months. The proportion of patients with progression as best response to treatment was 
higher in the poor prognosis patients compared with those with a favorable prognosis 
(23.8% vs. 15.4%). Similarly, in the poor prognosis group the proportion of patients 
who suffered from progression (80% vs. 50%) and died (80% vs. 21.4%) were also 
higher than in the favorable prognosis group.  Patients with poor prognosis suffered 
from progression earlier than the other patients (median PFS of 5.9 (CI95% 3.92-7.88) 
months in the poor prognosis group, 11.10 (CI95% 9.47-12.72) months in the 
intermediate prognosis group, and 17.97 (CI95% 2.09-33-85) months in the favorable 
prognosis  group 
   
 
3.3 Safety  
Two hundred and sixteen (96.4%) patients experienced at least one treatment-related 
AE of any grade. Common treatment-related adverse events were mostly grade 1 or 2, 
and only few grade 3 or 4 toxicities were observed (Table 4). Among the seven AEs in 
which severity was graded, the most common all-grade AEs (≥40%) were 
asthenia/fatigue and mucositis (Table 4). The most frequent grade-3 AEs were 
asthenia/fatigue (18.3%), hand-foot syndrome (6.2%), hypertension (5.8%) and 
mucositis (4.5%; Table 4). Only three cases of grade 4 toxicity were reported (Table 4). 
Other frequently reported all-grade AEs suffered by more than 10% of the patients 
included skin and hair color changes (19.2%), anemia (18.3%), leucopenia (14.3%), 
thrombocytopenia (13.8%), anorexia (13.4%) and increased creatinine (12.1%). 
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Treatment-related cardiac disorders were reported in 3 (1.3%) patients from the overall 
population. There were no treatment related deaths. PFS and OS were significantly 
higher for patients with sunitinib associated hypertension, hand-foot syndrome, 
neutropenia, diarrhea and mucositis (Table 5). The multivariate analysis identified 2 
independent  toxicities predictor for PFS and OS. Patients with hand-foot syndrome 
[(HR (CI95%) 0.619 (0.431-0.890)] or diarrhea [HR (CI95%) 0.483 (0.343-0.680) ] have 
increased the likelihood for PFS. Similarly patients with hand-foot syndrome [HR 
(CI95%) 0.508 (0.313-0.824)] or mucositis [HR (CI95%) 0.654 (0.430-0.997)] have 
increased the likelihood for OS. 
4. Discussion  
This analysis assessed the effectiveness and safety of sunitinib in three 
prospective translational studies in clinical practice.  In the present study, unlike the 
Pivotal trial7, 8 (Table 1), patients with ECOG PS ≥ 2 (12%), brain metastases (3%) or 
non-clear-cell histologies (7%) were also included. In addition, the proportion of 
patients with poor performance status, with intermediate-poor prognosis and non clear 
cell component was also higher than in the Pivotal trial (ECOG PS 1: 63.1 % vs. 38%; 
ECOG PS ≥ 2: 11.6 % vs. 0%;  MSKCC intermediate-poor prognosis: 93.8% vs. 62%; 
non clear cell component: 7% vs. 0%; Table 1). In spite of that, the efficacy data here 
presented, as in the expanded access trial of Sunitinib9, seem to resemble those obtained 
in the pivotal trial, supporting the fact that clinical practice with sunitinib mirrors 
clinical trials (Table 2). 
 In this pooled analysis, the median PFS (10.6 months) appeared to be also 
similar to that obtained in the pivotal trial (11 months). In line with our findings, Gore 
et al in the expanded access study with 4,543 patients [ECOG ≥2 (15%), brain 
metastases (7%), non-clear-cell histology (12%)] reported a median PFS of 9.4 months9  
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In the present pooled analysis, it should be noted the excellent long-term 
survival, particularly in the good-prognosis group. The rate of poor prognosis patients, 
non nephrectomized patients, patients with ECOG PS ≥ 2 and without clear cell 
component included in this analysis was higher than in the phase III pivotal trial (see 
Table 1) which could explain the lower median OS reported in this analysis vs. the 
pivotal trial. Poor prognosis patients had a bad outcome because although they are able to 
respond to treatment, they have a worse prognosis and they die earlier. In agreement with this, 
median OS reported in the expanded access trial, with an even higher rate of poor 
prognosis patients and patients with ECOG PS ≥ 2 and without clear cell component 
(see Table 1), was lower than in our analysis (18.7 months vs . 21.9 months). In addition 
this pooled analysis represents the first experience with sunitinib in our country. At the 
time of the study (2007-2011), the availability of second line options was still quite low. 
In fact, in some Spanish hospitals second line patients were directly derived to palliative 
options which could also explain the lower OS reported in this analysis vs, recent 
retrospective analysis in the real world setting16.  Regrettably, non further lines of 
treatment were collected in these three observational studies which have led to this 
pooled analysis of clinical data and we are not able to provide bibliography that 
supports this hypothesis either. Taking into account these data, the Spanish Oncology 
Genitourinary Group (SOGUG) decided to carry out a retrospective translational trial to 
search for clinical and molecular factors predictors of Sunitinib associated long term 
response comparing long responders with early refractory patients17. This observational, 
retrospective study included 97 patients with metastatic ccRCC who achieved PFS ≥22 
months, and 26 patients who showed progressive disease at first radiological evaluation. 
The proportion of patients with higher Fuhrman grade, metastasis at diagnosis, shorter 
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time from primary to metastatic diagnosis, no nephrectomy and brain, lung and hepatic 
metastasis was significantly higher in the primary refractory patient cohort. 
The safety profile seemed to be also comparable to the pivotal trial results. This 
assertion is supported by the observation that the overall incidence of most common 
related adverse events, dose reduction (55%) and discontinuations due to adverse events 
(19.9%) in this report were quite similar to those seen in the pivotal trial (50% and 
18.6% respectively). For any grade of AEs, the present study found comparable rates 
with those of the pivotal trial for fatigue/asthenia (71.9% vs. 75%), stomatitis/mucositis 
(55.8% vs. 56%), hypertension (35.7% vs. 30%) and hand-foot syndrome (34.8% vs. 
29%) and a lower rate of diarrhea (41.5% vs. 61%) and neutropenia (35.7% vs. 77%). 
Only hypothyroidism showed a higher rate greater compared with the pivotal trial 8 
(24.1% vs. 14%).   
 Some retrospective analyses have suggested that sunitinib-associated AEs are 
related to an improvement in clinical outcomes and could be considered as efficacy 
biomarkers 18-21. The fact that AEs seem to be linked to efficacy leads to the supposition 
that AEs identify patients with inherent pharmacokinetic and pharmacodynamic 
characteristics that predispose to clinical benefit and toxicity 22 . In the present study 
PFS and OS were significantly higher for patients suffering from sunitinib associated 
hypertension, hand-foot syndrome, neutropenia, diarrhea and mucositis. 
To obtain the greatest clinical benefit with sunitinib is important an appropriate 
management of toxicities through dose adjustments and treatment interruptions23 22, 24.  .  
Retrospective studies suggest that a change in schedule -not only in daily dose- 
can improve tolerability. Patients starting sunitinib with the recommended 50 mg/ day 
4/2 schedule in case of toxicity may show and improvement in their safety profile with a 
50 mg/day 2/1 schedule, 22, 23. There are ongoing studies that prospectively explore this 
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2/1 schedule (NCT02689167, NCT02398552, NCT01499121). This also leaves the 
possibility for other treatment schedules that may increase treatment tolerance based on 
these data.   
Certain limitations should be taken into consideration in relation to this analysis. 
Firstly, tumor assessment was performed according to local standard care, so efficacy 
data may not have been recorded in a homogeneous way. Furthermore, safety 
assessment was not an aim of the three studies herein analyzed, so this was evaluated 
based mainly on the documentation of the seven AEs in which severity was graded. 
Real world data are always required to confirm drug efficacy in a non-selected patient 
population. Recent data presented by Basappa et al, at ASCO GU 2017 from a Canadian 
database of first  line mRCC patients suggests significant improvement in OS and Time 
to Treatment Failure (TTF) with the use of sunitinib under an individualized approach 
(treatment starting at standard dose/schedule with subsequent schedule alterations to 
keep dose intensity, SI) vs. sunitinib use as per product monograph (SS) and even vs. 
pazopanib use as per product monograph (PS).  Median OS was improved in SI vs. SS 
(40.8 vs. 22.6 months, p<0.001) and SI vs. PS (40.8 vs. 20.3 m, p<0.001). TTF was 
better in SI vs. SS (16.6 vs. 5.4 m, p<0.001) and SI vs. PS (16.6 vs. 7.0 m, p<0.001)25. 
Our analysis represents first Spanish experience with sunitinib in daily clinical practice 
(data from patients treated  between 2007 to 2011),  prior to the use of an individualized 
approached to manage sunitinib associated toxicity. Efficacy outcomes in this real 
world setting resemble those obtained in the phase III pivotal trial with sunitinib where 
this individualized approach was not applied either. Further analysis is warranted to 
explore if this individualized approach with sunitinib can result like in the Canadian 




 This analysis shows that sunitinib provides efficacy outcomes in daily clinical 
practice that resemble those obtained in clinical trials and new treatment schedules 
appear to be changing the way of managing this drug without loss of efficacy.  
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Figure 1. Kaplan-Meier estimates. A), progression-free survival (PFS). B) PFS by 














Table 1. Baseline demographic and clinical characteristics 
 
 
Pooled analysis N 
N (224) 






Median age (range), years 64.1 (32.5-87.3) 62 (27-87) 59.0 (19.0-89.0)
Male 119 (69.2) 267 (71) 3364 (74) 
Clear cell component 205 (92.7) 375 (100) 4010 (88) 
Prior nephrectomy 181 (80.8) 340 (91) 4044 (89) 
ECOG PS 
  0 
  1 













MSKCC risk group 
  Favorable (0 risk factors) 
  Intermediate (1-2 risk factors) 













Number of metastatic sites 
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  1  
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Site of metastases 
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  Liver 




















Data are n (%). Missing data: age (12); sex (52); Histology (3); EGOG (10). EGOG PS: Eastern Cooperative 
Oncology Group performance status. MSKCC: Memorial Sloan-Kettering Cancer Center. Risk factors are low 
serum hemoglobin level, elevated corrected serum calcium level, elevated serum lactate dehydrogenase level, a 
poor performance status (ECOG ≥2 or Karnosfky <80%) and an interval of less than 1 year between diagnosis 
and systemic treatment. . 
*Motzer RJ et al. N Engl J Med 2007;356(2):115-124; data from sunitinib arm (N=375) 







Table 2. Median progression-free survival and overall survival 
 
 

















Overall PFS, months  10.6 (9.0-12.2) §11 (11-13) 9.4(8.8-10.0) 
£PFS by MKSCC risk, months   
   Favorable  17.9 (2.0-33.8) 14.9 (13.4-17.4) 15.0 (13.8-16.3 
   Intermediate 11.1 (9.4-12.7) *10.7 (8.3-11.4) 10.6 (9.4-11.1) 
   Poor 5.9 (3.9-7.8) *3.9 (2.5-13,5) 5.4 (5.1-5.7) 
Overall OS, months  21.9 (17.7-26-6) §26.4 (23.0-32.9) 18.7 (17.5-19.5) 
£OS by MKSCC risk, months    
   Favorable  - - 56.5 (41.6-NA) 
   Intermediate 22.4 (15.3-29.4) §20.7 (18.2-25.6) 20.0 (18.4-21.3) 
   Poor 7.7 (4.5-10.8) §5.3 (4.2-10.0) 9.1 (8.4-9.7) 
 
PFS: Progression-free survival. OS: Overall Survival. MSKCC: Memorial Sloan-Kettering 
Cancer Center 
£p>0.001 
*Motzer RJ et al. N Engl J Med 2007;356(2):115-124; §Motzer RJ et al. J Clin Oncol 
2009;27(22):3584-3590; data from Sunitinib arm (N=375) 
†Gore et al. Br J Cancer 2015;113(1):12-19   
 
Table 3. Tumor response  
 
 
Pooled analysis  
 






Complete response  11 (5.3)  11 (3) 63 (1) 
Partial response 80 (38.5) 165 (44) 597 (14) 
Stable disease  80 (38.5) 150 (40) 1893 (45) 
Progressive disease  37 (17.8) 26 (7) 800 (19) 
Objective response rate (CR+PR) 91 (43.8) 176 (47)** 660 (16) 
Disease control (PR+CR+SD) 171 (82) 326 (87) - 
Non evaluable 16 (7) - - 
 
Data are number of patients (%); A total of 208 patients 
*Motzer RJ et al. J Clin Oncol 2009;27(22):3584-3590; data from Sunitinib arm (N=375). 
†Gore et al. Br J Cancer 2015;113(1):12-19   
 **ORR evaluated by investigator-assessment at a time when around 45% of the patients had died in the study. 
In the first interim analysis, at a less mature stage (when only 13% of sunitinib patients had died) ORR by 




Table 4. Most common treatment-related adverse events 
Adverse Event All grades Grade 3 Grade 4 
Asthenia and fatigue 161 (71.9) 41 (18.3) 1 (0.4) 
Mucositis 125 (55.8) 11 (4.9) 1 (0.4) 
Diarrhea 93 (41.5) 9 (4.0) 0 
Neutropenia 80 (35.7) 10 (4.4) 1(0.4) 
Hypertension 80 (35.7) 13 (5.8) 0 
Hand-foot syndrome 78 (34.8) 14 (6.2) 0 
Hypothyroidism 54 (24.1) 1 (0.4) 0 
 
Data are number of patients (%). A total of 224 patients 
 
  
Table 5. Median progression-free survival and overall survival based on adverse events 
 PFS OS 
 No Yes p No Yes p 
Asthenia and fatigue N (62) N (161)  N (62) N (161)  
 11.6 (8.1-15.1) 10.5 (8.7-12.3) 0.094 20.1 (15.3-24.8) 22.2 (16.4-27.9) 0.998 
Mucositis N (98) N (125)  N (98) N (125)  
 9.2 (6.3-12.2) 11.5 (9.5 -13.7) 0.035 15.6 (9.8-21.3) 28.4 (20.9-35.8) 0.007 
Diarrhea N (130) N (93)  N (130) N (93)  
 8.7 (6.6-10.9) 15.2 (11.7-18.7) <0.001 18.4 (12.7-24.0) 29.9 (19.3-40.5) 0.005 
Neutropenia N (143) N (80)  N (143) N (80)  
 9.9 (7.7-12.2) 11.8 (9.6-13.9) 0.048 17.3 (13.1-21.6) - <0.001 
Hand-foot syndrome N (145) N (78)  N (145) N (78)  
 8.6 (6.3-10.4) 13.7 (10.6-16.9) <0.001 15.6 (10.5-20.6) 28.7 (-) <0.001 
Hypertension N (143) N (80)  N (143) N (80)  
 9.6 (7.7-11.5) 12.1 (10.4-13.8) 0.031 17.3 (12.5-22.1) 29.2 (25.1-33.2) <0.001 
Hypothyroidsm N (169) N (54)  N (169) N (54)  
 10.3 (8.5-12.1) 11.8 (7.6-15.9) 0.134 20.1 (15.4-24.8) 28.4 (20.7-36.1) 0.075 
PFS progression free survival; OS Overall survival  
Data are median PFS (IC95%) and median OS (IC95%), months 
 
 
